Canada: Amendments To The Patented Medicines (Notice Of Compliance) Regulations And The Data Protection Regulations Are Now In Force

Last Updated: October 12 2006

Article by Eileen McMahon, Conor McCourt and Ingrid VanderElst

On October 5, 2006, amendments to the Patented Medicines (Notice of Compliance) Regulations (PM(NOC) Regulations) and the Food and Drug Regulations (commonly referred to as the "Data Protection Regulations") came into force. The PM(NOC) Regulations create the regulatory framework that applies to pharmaceutical patents to be listed on Health Canada’s Patent Register. The Data Protection Regulations create the regulatory framework that applies to protect data in regulatory submissions. The amendments are the culmination of significant stakeholder consultation and two earlier versions of the regulations. The key amendments are discussed below.

PM(NOC) Regulations

The PM(NOC) Regulations permit a manufacturer of an innovative drug to submit certain patents for inclusion on the Patent Register in connection with the filing of a New Drug Submission or a Supplement to a New Drug Submission. The Patent Register lists patents that relate to innovative drugs that have been approved for sale by the Minister of Health.

Listed patents have certain protections. When marketing approval is sought for a generic drug through comparison to an innovative product for which there is a listed patent, the generic drug manufacturer must either accept that the marketing approval cannot be issued until expiry of the listed patent or serve the manufacturer of the innovative product with a "notice of allegation". The notice must specify why the listed patent should not prevent the generic drug from coming to market as soon as marketing approval is obtained. The PM(NOC) Regulations permit the manufacturer of the innovative drug to commence legal proceedings in response to the notice of allegation. The proceedings trigger an automatic stay of marketing approval for the generic product for up to 24 months.

The amendments to the PM(NOC) Regulations change the regime in several important ways. They restrict the types of patents that may be listed on the Patent Register. A patent is eligible for listing against a New Drug Submission if it contains claims to the medicinal ingredient, formulation, dosage form or indication for which drug regulatory approval is sought. A "claim to a medicinal ingredient" includes a claim for different polymorphs, but no such recognition is given for claims to other forms of a medicinal ingredient (e.g., salts, esters, enantiomers or solvates). A patent is eligible for listing against a Supplement to a New Drug Submission only if it contains claims to the formulation, dosage form or indication for which drug regulatory approval is sought. A claim for the formulation is defined as a claim for a substance that is a mixture of medicinal and non-medicinal ingredients in a drug and that is administered to a patient in a particular dosage form; a claim for the dosage form is defined as a claim for a delivery system for administering a medicinal ingredient in a drug or a formulation of a drug that includes within its scope that medicinal ingredient or formulation. According to the Regulatory Impact Analysis Statement (RIAS), the requirement for a specific patent claim is meant to ensure that a patent directed solely to a device, such as an intravenous stand or syringe, is not eligible for listing as a patent directed to a dosage form. The RIAS states that dosage forms include controlled-release tablets and capsules, implants and transdermal patches.

The new patent listing eligibility requirements do not apply to patent lists submitted before June 17, 2006.

The amendments also restrict the types of drug regulatory submissions that will support a patent listing. Specifically excluded from a Supplement to a New Drug Submission for which patents can be listed are (i) brand name changes, (ii) manufacturing site changes, (iii) process changes, (iv) quality control (specification) changes, (v) label changes, (vi) safety profile changes, and (vii) withdrawal period amendments. Supplements to New Drug Submissions for dosage form, formulation or indication changes will support a patent listing.

The amendments also limit the requirements for a generic drug manufacturer to address patents listed on the Patent Register. A generic drug manufacturer must issue a notice of allegation for only those patents on the Patent Register as of the date of filing its submission. In most cases, generic drug manufacturers that have already filed a submission benefit from these limitations through a transitional rule that deems the filing date of the submission to be the date that the amendments come into force (i.e., October 5, 2006). If the generic drug manufacturer’s submission for approval was filed less than six years from the date when a Notice of Compliance was issued for the innovative drug, the generic drug manufacturer will be required to address patents added to the Patent Register during the six-year period dating from the issuance of the first Notice of Compliance.

The amendments also expand the type of allegation that a generic drug manufacturer may make in a notice of allegation. In addition to allegations that the proposed product will not infringe the listed patent and/or that the listed patent is invalid, it may be alleged that (i) the manufacturer of the innovative drug has falsely certified a patent’s eligibility for inclusion on the Patent Register, and (ii) the generic drug manufacturer is not seeking approval for the claimed use. A generic drug manufacturer cannot avoid serving a notice of allegation by maintaining that its drug regulatory submission does not seek approval for a patented use. However, according to the RIAS, this is meant to ensure that, in assessing infringement of a use patent, the court’s inquiry is to be limited to a consideration of whether acts of infringement will occur by or at the behest of the generic drug manufacturer (i.e., the court may not consider whether activities by physicians or pharmacists may result in infringement). The amendments require a notice of allegation whether the approval for a generic drug is sought through an Abbreviated New Drug Submission or otherwise. According to the RIAS, this is meant to ensure that the PM(NOC) Regulations apply to "hybrid" or "paper" New Drug Submissions when approval is sought on the basis of a direct or an indirect comparison or reference to an innovative drug. A generic drug manufacturer is required to retract a notice of allegation if the submission for drug approval is cancelled. Moreover, the Minister of Health is required to delete from the Patent Register patents relating to drugs whose Drug Identification Numbers have been cancelled (other than by reason of a change in manufacturer). As the reason for the cancellation is not always apparent, the Minister’s duty is subject to a 90-day grace period. Finally, except for proceedings commenced before October 5, 2006, courts are not permitted to award profits to compensate a generic drug manufacturer for delay in obtaining a Notice of Compliance as a result of proceedings brought under the PM(NOC) Regulations.

Data Protection Regulations

In Canada, a generic drug is generally approved for sale following a demonstration that the generic product is bioequivalent to an approved drug. Bioequivalence typically involves a comparison between the generic drug and the original, innovative product. The previous data protection provisions in the Food and Drug Regulations were intended to guarantee the confidentiality and non-use of the data relating to the innovative drug and prevent a generic drug manufacturer from obtaining drug approval for a period of five years from the date that the innovative drug obtained a Notice of Compliance. However, the provisions were so narrowly interpreted by the courts as to be virtually ineffective.

The amendments to the Data Protection Regulations enhance the protections for data relating to an innovative drug by prohibiting the granting of a Notice of Compliance to a manufacturer that seeks approval of a product on the basis of "a direct or indirect comparison to an innovative drug". According to the RIAS, this is meant to include submissions for approval of generic drugs made through either an Abbreviated New Drug Submission or a New Drug Submission. The period of data protection is eight years from the date that the innovative drug obtained a Notice of Compliance. Pediatric data are eligible for an additional six-month period of protection if submitted with the New Drug Submission or with a Supplement to a New Drug Submission filed within five years after the issuance of the first Notice of Compliance. There is also a six-year no-filing period (within the eight-year term of protection) during which a generic drug manufacturer is not permitted to file a submission for drug approval. The data protections cease to apply if the innovative drug is no longer being marketed in Canada.

The "innovative drugs" that qualify for the data protection provisions are drugs that (i) contain a medicinal ingredient that has not previously been approved in a drug; and (ii) are not variations of a previously approved medicinal ingredient, such as a salt, an ester, an enantiomer, a solvate or a polymorph. According to the RIAS, minor variations of the medicinal ingredient are not entitled to separate terms of data protection; nor are additional terms of data protection available for drugs that contain combinations of medicinal ingredients that have already been approved. The RIAS states that other variations, such as metabolites, may qualify for the protections provided that marketing approval is sought on the basis of new and significant clinical data, rather than previously submitted data.

According to the transitional provision, data in submissions for which Notices of Compliance were issued before June 17, 2006 do not have the benefit of the enhanced data protections.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.